Q-omics provides the consensus-scored VSTM2A-OT1 profile across patient tissues and cancer cell-line models. VSTM2A-OT1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, VSTM2A-OT1 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, VSTM2A-OT1 RNA expression shows 9,714 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LGG, COAD, and KIRP as cancer lineages where VSTM2A-OT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VSTM2A-OT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VSTM2A-OT1 survival associations across molecular data types. VSTM2A-OT1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VSTM2A-OT1 RNA expression–survival associations across cancer types. High VSTM2A-OT1 expression shows unfavorable associations in KIRC, SKCM and ACC, but favorable associations in LGG, BLCA and BRCA. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for VSTM2A-OT1 RNA expression.
This table summarizes VSTM2A-OT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for VSTM2A-OT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VSTM2A-OT1 shows lower tumor expression in COAD, STAD, THCA and READ and higher tumor expression in BRCA and KIRP. The COAD box plot shows higher VSTM2A-OT1 RNA expression in normal versus tumor tissue (log2 FC = −0.224, t-test p < 0.001).
This table shows molecular features associated with VSTM2A-OT1 in patient tissues and cancer cell lines. In patient samples, VSTM2A-OT1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
